As the country returns to work, employers need to consider how best to decrease the possible spread of COVID-19 and lower the potential impact to their workforce. Until a vaccine is available, COVID-19 screening provides employers with an additional tool to help them in their decisions to reopen their businesses while striving to reduce the risk to their employees and customers of COVID-19 exposure.
*Testing Disclosure: This viral marker test (molecular via RT-PCR) has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by Clinical Reference Laboratory, Inc. located in Lenexa, KS. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the authorization is terminated or revoked sooner.